Take a poll of most of biotech’s venture capitalists—the ones that survived the financial crash, anyway—and you might find that just about all of them have reloaded with new funds over the past few years. Today, you can add Clarus Ventures to the list.
Clarus—a VC firm with offices in the bi-coastal biotech hotbeds of Cambridge, MA, and South San Francisco, CA—has raised its third fund, a $500 million haul called Clarus Lifesciences III LP that’ll it’ll use to invest in both early and mature drug developers.